Litcius/Paper detail

LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study

Ramaprasad Srinivasan, Othon Iliopoulos, W. Kimryn Rathmell, Veena M. Narayan, Benjamin L. Maughan, Stéphane Oudard, Tobi Else, Jodi K. Maranchie, Sarah J. Welsh, Ane B. Iversen, K. Chen, Rodolfo F. Perini, Y. Liu, W. M. Linehan, Eric Jonasch

2022Annals of Oncology14 citationsDOI

Topics & Concepts

MedicineDiscontinuationClinical endpointInternal medicineVon Hippel–Lindau diseaseRenal cell carcinomaProgressive diseaseTolerabilityPhases of clinical researchClear cell renal cell carcinomaNeuroendocrine tumorsOncologyGastroenterologySurgeryDiseaseToxicityAdverse effectClinical trialCancer, Hypoxia, and MetabolismCancer-related Molecular PathwaysAdrenal and Paraganglionic Tumors
LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study | Litcius